(Q46846035)

25 December 2017

title

Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma (English)

1 reference

25 December 2017

1 reference

1 reference

1 reference

Se Hoon Park

1

1 reference

25 December 2017

Yeon Ho Park

2

1 reference

25 December 2017

Jeong Nam Lee

3

1 reference

25 December 2017

Soo-Mee Bang

4

1 reference

25 December 2017

Eun Kyung Cho

5

1 reference

25 December 2017

Dong Bok Shin

6

1 reference

25 December 2017

Jae Hoon Lee

7

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

25 December 2017

published in

Cancer

1 reference

25 December 2017

volume

106

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

361-365

1 reference

25 December 2017

Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

The role of chemotherapy in the treatment of bile duct cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Biliary tract neoplasms: update 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Intrahepatic cholangiocarcinoma in Korea

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21621

7 January 2021

Identifiers

DOI

10.1002/CNCR.21621

1 reference

25 December 2017

1 reference

25 December 2017